Halozyme Therapeutics | HALO - Bénéfice Avant Impôts

Prix De L'Action
67.82
Variation Quotidienne
0.74 1.10%
Mensuellement
2.02%
Annuel
12.62%
Q2 Prévisions
65.97




Bénéfice Avant Impôts Changement Date
Acadia Pharmaceuticals USD 26.32M 18.28M 2025-12
Agios Pharmaceuticals USD -109.06M 5.62M 2025-12
Alnylam Pharmaceuticals USD 161.14M 77.83M 2025-12
Amarin USD -852K 7.26M 2025-12
Amgen USD 3.92B 2.35B 2025-09
Baxter International USD 121M 12M 2025-09
Cara Therapeutics USD -4.91M 3.17M 2025-03
Cytokinetics USD -183.03M 123.15M 2025-12
DBV Technologies USD -33.16M 8.6M 2025-09
Eli Lilly USD 7.23B 456M 2025-09
Esperion Therapeutics USD 63.67M 95M 2025-12
Halozyme Therapeutics USD 218.96M 14.02M 2025-09
Intrexon USD -60.48M 27.09M 2024-06
Ionis Pharmaceuticals USD -228M 99M 2025-12
MannKind USD -20.93M 28.71M 2025-12
Minerva Neurosciences USD 22.51M 30.74M 2024-09
Nektar Therapeutics USD -34.7M 2.35M 2025-12
Pfizer USD 3.33B 290M 2025-09
Rigel Pharmaceuticals USD -1.03M 7.22M 2024-06
United Therapeutics USD 444M 6M 2025-12
Vanda Pharmaceuticals USD -22.92M 16.68M 2024-12